Page 61 - Read Online

Bibi et al. J Transl Genet Genom 2024;8:119-161 https://dx.doi.org/10.20517/jtgg.2023.50 Page 151

3. Gurel B, Lucia MS, Thompson IM Jr, et al. Chronic inflammation in benign prostate tissue is associated with high-grade prostate
cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2014;23:847-56. DOI PubMed
PMC
4. Sfanos KS, De Marzo AM. Prostate cancer and inflammation: the evidence. Histopathology 2012;60:199-215. DOI PubMed PMC
5. Sfanos KS, Isaacs WB, De Marzo AM. Infections and inflammation in prostate cancer. Am J Clin Exp Urol 2013;1:3-11.
PubMed PMC
6. Cai T, Santi R, Tamanini I, et al. Current knowledge of the potential links between inflammation and prostate cancer. Int J Mol Sci
2019;20:3833. DOI PubMed PMC
7. Saxby H, Boussios S, Mikropoulos C. Androgen receptor gene pathway upregulation and radiation resistance in oligometastatic
prostate cancer. Int J Mol Sci 2022;23:4786. DOI PubMed PMC
8. Sfanos KS, Bruno TC, Maris CH, et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin
Cancer Res 2008;14:3254-61. DOI PubMed PMC
9. Bubendorf L, Schöpfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol
2000;31:578-83. DOI
10. Bilusic M, Madan RA, Gulley JL. Immunotherapy of prostate cancer: facts and hopes. Clin Cancer Res 2017;23:6764-70. DOI
PubMed PMC
11. Markowski MC, Shenderov E, Eisenberger MA, et al. Extreme responses to immune checkpoint blockade following bipolar androgen
therapy and enzalutamide in patients with metastatic castration resistant prostate cancer. Prostate 2020;80:407-11. DOI PubMed
PMC
12. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med
2015;373:1803-13. DOI PubMed PMC
13. Luke JJ, Rutkowski P, Queirolo P, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC
melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet 2022;399:1718-29. DOI
14. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl
J Med 2018;378:1277-90. DOI
15. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl
J Med 2015;373:23-34. DOI
16. Petrylak DP, de Wit R, Chi KN, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or
metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet
2017;390:2266-77. DOI
17. Lee NY, Ferris RL, Psyrri A, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients
with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre,
phase 3 trial. Lancet Oncol 2021;22:450-62. DOI
18. Boussios S, Rassy E, Shah S, Ioannidou E, Sheriff M, Pavlidis N. Aberrations of DNA repair pathways in prostate cancer: a
cornerstone of precision oncology. Expert Opin Ther Targets 2021;25:329-33. DOI PubMed
19. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO -associated clonal T cell proliferation in two patients after gene therapy
2
for SCID-X1. Science 2003;302:415-9. DOI
20. High KA, Roncarolo MG. Gene therapy. N Engl J Med 2019;381:455-64. DOI PubMed
21. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009;458:719-24. DOI
22. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N
Engl J Med 1991;324:1156-61. DOI
23. Cooperberg MR, Broering JM, Carroll PR. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J
Natl Cancer Inst 2009;101:878-87. DOI PubMed PMC
24. Koeneman KS, Kao C, Ko SC, et al. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J Urol
2000;18:102-10. DOI
25. Madan RA, Gulley JL. Finding an immunologic beachhead in the prostate cancer microenvironment. J Natl Cancer Inst
2019;111:219-20. DOI PubMed PMC
26. Liu G, Lu S, Wang X, et al. Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis. J Clin Invest
2013;123:4410-22. DOI PubMed PMC
27. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR. Prevalent expression of the immunostimulatory MHC class I
chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 2004;114:560-8. DOI PubMed PMC
28. Healy CG, Simons JW, Carducci MA, et al. Impaired expression and function of signal-transducing zeta chains in peripheral T cells
and natural killer cells in patients with prostate cancer. Cytometry 1998;32:109-19. DOI
29. Pal SK, Moreira D, Won H, et al. Reduced T-cell numbers and elevated levels of immunomodulatory cytokines in metastatic prostate
cancer patients de novo resistant to abiraterone and/or enzalutamide therapy. Int J Mol Sci 2019;20:1831. DOI
30. Lopez-Bujanda Z, Drake CG. Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies. J Leukoc
Biol 2017;102:393-406. DOI PubMed PMC
31. Idorn M, Køllgaard T, Kongsted P, Sengeløv L, Thor Straten P. Correlation between frequencies of blood monocytic myeloid-derived